Biotech Values

[iwfal]

XOMA -

A Gevokizumab BLA based on EYEGUARD-B only* would have only a Behçet’s indication rather than a general NIU indication. Since the Behçet’s prevalence is many times smaller than the general NIU prevalence, a Behçet’s-only indication would require that Gevokicumab carry a very high price to produce commercially meaningful sales.

For a while now they appear to have been looking for a way to get an orphan indication as the first indication. I would presume in order to take advantage of priming (setting the initial price very high).

That said, clearly they will need to dillute. Presumably soon - while the market is hot.

Finally note that previously I commented on their late schedule pop for osteo. Apparently a pattern.